Publication: Characteristics, treatment patterns, prognostic determinants and outcome of peripheral T cell lymphoma and natural killer/T cell non-Hodgkin Lymphoma in older patients: The result of the nationwide multi-institutional registry Thai Lymphoma Study Group
| dc.contributor.author | Wudhikarn K. | |
| dc.contributor.author | Bunworasate U. | |
| dc.contributor.author | Julamanee J. | |
| dc.contributor.author | Lekhakula A. | |
| dc.contributor.author | Ekwattanakit S. | |
| dc.contributor.author | Khuhapinant A. | |
| dc.contributor.author | Chuncharunee S. | |
| dc.contributor.author | Niparuck P. | |
| dc.contributor.author | Numbenjapon T. | |
| dc.contributor.author | Prayongratana K. | |
| dc.contributor.author | Kanitsap N. | |
| dc.contributor.author | Wongkhantee S. | |
| dc.contributor.author | Makruasi N. | |
| dc.contributor.author | Wong P. | |
| dc.contributor.author | Norasetthada L. | |
| dc.contributor.author | Nawarawong W. | |
| dc.contributor.author | Sirijerachai C. | |
| dc.contributor.author | Chansung K. | |
| dc.contributor.author | Suwanban T. | |
| dc.contributor.author | Praditsuktavorn P. | |
| dc.contributor.author | Intragumtornchai T. | |
| dc.contributor.author | On Behalf Of Thai Lymphoma Study Group | |
| dc.date.accessioned | 2021-04-05T03:02:05Z | |
| dc.date.available | 2021-04-05T03:02:05Z | |
| dc.date.issued | 2020 | |
| dc.date.issuedBE | 2563 | |
| dc.description.abstract | Introduction: Peripheral T cell NHL (PTCL) and natural killer/T cell NHL (NKTCL) are relatively rare disorders. Data on clinical presentation, treatment and outcome are limited especially in older age groups. Methods: We identified 127 patients with PTCL and NKTCL, excluding cutaneous T/NK cell lymphoma, aged over 60 years old from Thailand nationwide multicenter registry. Results: Of 127 patients, median age of diagnosis was 67 years old. Patients aged older than 75 years old had similar characteristics to younger (60–74 years old) but higher comorbidity index. Seventy-nine patients (62.2%) received intensive/definite multi-agent chemotherapy, however, the proportion was significant lower in older patients (70.4% vs 34.5%, p <. 001). After a median follow up duration of 17.3 months, 2-year progression free survival and overall survival were 38.1% and 48.5%. Univariate and multivariable analysis demonstrated older age, poor performance status and absence of definite multi-agent chemotherapy were associated with inferior survival. Definite multi-agent lymphoma specific chemotherapy was an independent factor for overall survival after adjustment for age, comorbidity index, performance status and prognostic index for T cell lymphoma. Conclusion: Despite overall poor prognosis of PTCL and NKTCL in older adults, chemotherapy could result in objective response and long-term survival in selected patients of this vulnerable age group thus emphasizing the importance of comprehensive geriatric evaluation. © 2019 | |
| dc.format.mimetype | application/pdf | |
| dc.identifier.citation | Journal of Geriatric Oncology. Vol 11, No.1 (2020), p.62-68 | |
| dc.identifier.doi | 10.1016/j.jgo.2019.03.016 | |
| dc.identifier.issn | 18794068 | |
| dc.identifier.other | 2-s2.0-85063582476 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.14740/4948 | |
| dc.rights.holder | Scopus | |
| dc.subject.other | Asparaginase | |
| dc.subject.other | Cyclophosphamide | |
| dc.subject.other | Dexamethasone | |
| dc.subject.other | Doxorubicin | |
| dc.subject.other | Etoposide | |
| dc.subject.other | Ifosfamide | |
| dc.subject.other | Methotrexate | |
| dc.subject.other | Prednisolone | |
| dc.subject.other | Steroid | |
| dc.subject.other | Vincristine | |
| dc.subject.other | Adult | |
| dc.subject.other | Aged | |
| dc.subject.other | Aging | |
| dc.subject.other | Article | |
| dc.subject.other | Cancer chemotherapy | |
| dc.subject.other | Cancer combination chemotherapy | |
| dc.subject.other | Cancer prognosis | |
| dc.subject.other | Cancer radiotherapy | |
| dc.subject.other | Cancer registry | |
| dc.subject.other | Cohort analysis | |
| dc.subject.other | Comorbidity | |
| dc.subject.other | Controlled study | |
| dc.subject.other | Diarrhea | |
| dc.subject.other | Drug dose escalation | |
| dc.subject.other | Drug fatality | |
| dc.subject.other | Drug safety | |
| dc.subject.other | Febrile neutropenia | |
| dc.subject.other | Female | |
| dc.subject.other | Follow up | |
| dc.subject.other | Geriatric assessment | |
| dc.subject.other | Groups by age | |
| dc.subject.other | Human | |
| dc.subject.other | Ileus | |
| dc.subject.other | Infection | |
| dc.subject.other | Intensive care | |
| dc.subject.other | Long term survival | |
| dc.subject.other | Major clinical study | |
| dc.subject.other | Male | |
| dc.subject.other | Multiple cycle treatment | |
| dc.subject.other | Neuropathy | |
| dc.subject.other | Neutropenia | |
| dc.subject.other | NK T cell lymphoma | |
| dc.subject.other | Nonhodgkin lymphoma | |
| dc.subject.other | Oral mucositis | |
| dc.subject.other | Overall survival | |
| dc.subject.other | Peripheral T cell lymphoma | |
| dc.subject.other | Physical performance | |
| dc.subject.other | Polypharmacy | |
| dc.subject.other | Priority journal | |
| dc.subject.other | Progression free survival | |
| dc.subject.other | Thailand | |
| dc.subject.other | Thrombocytopenia | |
| dc.subject.other | Treatment outcome | |
| dc.title | Characteristics, treatment patterns, prognostic determinants and outcome of peripheral T cell lymphoma and natural killer/T cell non-Hodgkin Lymphoma in older patients: The result of the nationwide multi-institutional registry Thai Lymphoma Study Group | |
| dc.type | Article | |
| dspace.entity.type | Publication | |
| swu.datasource.scopus | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85063582476&doi=10.1016%2fj.jgo.2019.03.016&partnerID=40&md5=3ef0840820bce919d55b06f2fc54bb86 |
